BFEC
EBS icon

Benjamin F. Edwards & Company’s Emergent Biosolutions EBS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2
Closed – – 1113
2015
Q4 		$0 Buy
+2
New +$70 ﹤0.01% 1160

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Benjamin F. Edwards & Company's EBS Position: Q1 2016 in Review

Benjamin F. Edwards & Company sold out of Emergent Biosolutions (EBS) in Q1 2016, closing a stake of 2 shares.

Benjamin F. Edwards & Company first reported a position in EBS in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 214 funds tracked by Wall St. Rank hold EBS as of Q1 2016.

  • Benjamin F. Edwards & Company reported no remaining Emergent Biosolutions position as of Q1 2016 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 2 Emergent Biosolutions shares in Q1 2016.
  • Benjamin F. Edwards & Company first reported a position in Emergent Biosolutions in Q4 2015 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Emergent Biosolutions position peaked at $0 in Q4 2015.
  • 214 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2016.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2016, filed 13 Apr 2016.